Literature DB >> 15361551

Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2.

Yong-Fu Xiao1, Qingen Ke, John M Seubert, J Alyce Bradbury, Joan Graves, Laura M Degraff, John R Falck, Kris Krausz, Harry V Gelboin, James P Morgan, Darryl C Zeldin.   

Abstract

CYP2J2 is abundant in cardiomyocytes and is involved in the metabolism of arachidonic acid (AA) to epoxyeicosatrienoic acids (EETs), which affect multiple cell functions. In this study, we investigated the effect of overexpression of CYP2J2 on cardiac L-type Ca2+ currents (ICa) in adult transgenic mice. Cardiac-specific overexpression of CYP2J2 was achieved using the alpha-myosin heavy chain promoter. ICa was recorded from isolated ventricular cardiomyocytes. Compared with the wild-type cardiomyocytes (n = 60), the density of ICa was significantly increased by 40 +/- 9% in the CYP2J2 transgenic cardiomyocytes (n = 71; P < 0.001). N-Methylsulfonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH), a specific inhibitor of EET biosynthesis, and clotrimazole, a cytochrome P450 inhibitor, significantly reduced ICa in both wild-type and transgenic cardiomyocytes; however, MS-PPOH inhibited ICa to a greater extent in the CYP2J2 transgenic cells (n = 10) than in the wild-type cells (n = 10; P < 0.01). Addition of 11,12-EET significantly restored ICa in MS-PPOH-treated cells. Intracellular dialysis with either of two inhibitory monoclonal antibodies against CYP2J2 significantly reduced ICa in both wild-type and transgenic mice. Membrane-permeable 8-bromo-cAMP and the beta-adrenergic agonist isoproterenol significantly reversed the monoclonal antibody-induced inhibition of ICa. In addition, the total protein level of the alpha1 subunit of the Cav1.2 L-type Ca2+ channel was not altered in CYP2J2 transgenic hearts, but the phosphorylated portion was markedly increased. In conclusion, overexpression of CYP2J2 increases ICa in CYP2J2 transgenic cardiomyocytes via a mechanism that involves cAMP-protein kinase A-dependent phosphorylation of the L-type Ca2+ channel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361551     DOI: 10.1124/mol.104.004150

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues.

Authors:  Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

2.  CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].

Authors:  Michael Zhuo Wang; Janelle Y Saulter; Etsuko Usuki; Yen-Ling Cheung; Michael Hall; Arlene S Bridges; Greg Loewen; Oliver T Parkinson; Chad E Stephens; James L Allen; Darryl C Zeldin; David W Boykin; Richard R Tidwell; Andrew Parkinson; Mary F Paine; James Edwin Hall
Journal:  Drug Metab Dispos       Date:  2006-09-22       Impact factor: 3.922

3.  Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms.

Authors:  Tong Lu; Dan Ye; Xiaoli Wang; John M Seubert; Joan P Graves; J Alyce Bradbury; Darryl C Zeldin; Hon-Chi Lee
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

4.  Common variation in fatty acid metabolic genes and risk of incident sudden cardiac arrest.

Authors:  Rozenn N Lemaitre; Catherine O Johnson; Stephanie Hesselson; Nona Sotoodehnia; Nona Sotoodhenia; Barbara McKnight; Colleen M Sitlani; Thomas D Rea; Irena B King; Pui-Yan Kwok; Angel Mak; Guo Li; Jennifer Brody; Eric Larson; Dariush Mozaffarian; Bruce M Psaty; Adriana Huertas-Vazquez; Jean-Claude Tardif; Christine M Albert; Leo-Pekka Lyytikäinen; Dan E Arking; Stefan Kääb; Heikki V Huikuri; Bouwe P Krijthe; Mark Eijgelsheim; Ying A Wang; Kyndaron Reinier; Terho Lehtimäki; Sara L Pulit; Ramon Brugada; Martina Müller-Nurasyid; Chris H Newton-Cheh; Pekka J Karhunen; Bruno H Stricker; Philippe Goyette; Jerome I Rotter; Sumeet S Chugh; Aravinda Chakravarti; Xavier Jouven; David S Siscovick
Journal:  Heart Rhythm       Date:  2014-01-10       Impact factor: 6.343

Review 5.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

6.  Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct.

Authors:  Peng Sun; Wen Liu; Dao-Hong Lin; Peng Yue; Rowena Kemp; Lisa M Satlin; Wen-Hui Wang
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 7.  Eicosanoid signalling pathways in the heart.

Authors:  Christopher M Jenkins; Ari Cedars; Richard W Gross
Journal:  Cardiovasc Res       Date:  2008-12-14       Impact factor: 10.787

8.  Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2.

Authors:  Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Arch Biochem Biophys       Date:  2007-04-10       Impact factor: 4.013

9.  Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice.

Authors:  Qingen Ke; Yong-Fu Xiao; J Alyce Bradbury; Joan P Graves; Laura M Degraff; John M Seubert; Darryl C Zeldin
Journal:  Mol Pharmacol       Date:  2007-07-24       Impact factor: 4.436

10.  Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.

Authors:  Michael Zhuo Wang; Judy Qiju Wu; Arlene S Bridges; Darryl C Zeldin; Sally Kornbluth; Richard R Tidwell; James Edwin Hall; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2007-08-20       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.